The presence of cirrhosis increases the mortality of patients with peptic ulcer bleeding (PUB). Both acute variceal bleeding (AVB) and PUB are associated with substantial mortality in cirrhosis. This multicenter cohort study was performed to assess whether the mortality of patients with cirrhosis with PUB is different from that of those with AVB. Patients with cirrhosis and acute gastrointestinal bleeding were consecutively included and treated with somatostatin and proton pump inhibitor infusion from admission and with antibiotic prophylaxis. Emergency endoscopy with endoscopic therapy was performed within the first 6 hours. 646 patients with AVB and 144 with PUB were included. There were baseline differences between groups, such as use of gastroerosive drugs or b-blockers. Child-Pugh and Model for End-Stage Liver Disease MELD scores were similar. Further bleeding was more frequent in the AVB group than those in the PUB group (18% vs. 10%; odds ratio [OR] 5 0.50; 95% confidence interval [CI] 5 0.29-0.88). However, mortality risk at 45 days was similar in both groups (19% in the AVB group vs. 17% in the PUB group; OR 5 0.85; 95% CI 5 0.55-1.33; P 5 0.48). Different parameters, such as ChildPugh score, acute kidney injury, acute on chronic liver failure, or presence of shock or bacterial infection, but not the cause of bleeding, were related to the risk of death. Only 2% of the PUB group versus 3% of the AVB group died with uncontrolled bleeding (P 5 0.39), whereas the majority of patients in either group died from liver failure or attributed to other comorbidities. Conclusion: Using current first-line therapy, patients with cirrhosis and acute peptic ulcer bleeding have a similar survival than those with variceal bleeding. The risk of further bleeding is higher in patients with variceal hemorrhage. However, few patients in both groups died from uncontrolled bleeding, rather the cause of death was usually related to liver failure or comorbidities. (HEPATOLOGY 2018;67:1458-1471.
therapeutic management of critically ill patients and in specific hemostatic therapy have led to a marked reduction in mortality from AVB, from rates greater than 40% to around 20% of cases, (5) (6) (7) whereas mortality from PUB has also improved significantly. (7, 8) Currently, comorbidity largely contributes to mortality from UGIB, whereas death attributed to uncontrolled bleeding has decreased markedly. (9) (10) (11) (12) (13) (14) Observational studies have shown that mortality among patients with PUB is much higher in those with cirrhosis than in those without chronic liver disease. (2, 9, 11) In patients with cirrhosis and PUB, mortality rates of up to 15%-20% of cases have been reported in recent years, (2, 3, 15) which are comparable with current mortality from AVB. (16, 17) However, it has not been clarified whether at present, in patients with cirrhosis, the prognosis of those with AVB differs from those with PUB. This may have relevant implications in the management of patients that could contribute to further improvements in survival.
The aim of this study was to assess whether, with current first-line therapies, the risk of mortality, and the risk of further bleeding of patients with cirrhosis with acute PUB are comparable to those of patients with cirrhosis with AVB.
Patients and Methods
From July 2005 to July 2012, all consecutive patients admitted with UGIB were considered for inclusion in this multicenter cohort study involving five Spanish hospitals with a gastrointestinal bleeding register (Hospital de Sant Pau in Barcelona, Hospital de Bellvitge in Hospitalet, Hospital Arnau de Vilanova in Lleida, Hospital Parc Taul ı in Sabadell, and Hospital de Matar o). The Ethics Committee of all the included centers approved the study protocol. The study was conducted according to the guidelines of the Declaration of Helsinki and the applicable provisions of Good Clinical Practice in clinical trials. All data were gathered in the context of standard practice from the clinical records of the patients and were anonymized and collected in a protected database. No specific procedures were conducted for the study, and informed consent was not required.
SELECTION OF PATIENTS
All patients admitted with hematemesis (or bloody nasogastric aspirate) and/or melena confirmed by the hospital staff, with cirrhosis of any etiology and aged over 18 years, were considered for inclusion. Cirrhosis was diagnosed by previous liver biopsy or by clinical, biochemical, and imaging studies.
In order to adapt the study to the real-world setting, few exclusion criteria were used. Patients only were excluded if they had one or more of the following criteria: bleeding from sources different to esophageal varices or peptic ulcersuch as gastric varices or portal hypertension (PHT) gastropathy, among others, previous transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt, Child-Pugh >12, advanced hepatocellular carcinoma, massive bleeding resulting in balloon tamponade or death before endoscopy, noncirrhotic PHT, and previous decision to avoid specific medical therapy.
STUDY DESIGN AND TREATMENTS
All patients underwent emergency endoscopy, and those in whom gastroscopy disclosed bleeding from esophageal varices or bleeding from a peptic ulcer were included in the study. Primary and secondary outcomes were compared between these two groups of patients by a retrospective review of the clinical records of patients consecutively included in a prospective register of admissions attributed to UGIB. In all the participating hospitals, patients were managed applying uniform criteria for diagnosis and treatment, which were performed following standards of care according to recommendations from international consensus workshops. (18) (19) (20) (21) All patients received from admission a continuous intravenous infusion of somatostatin (SMT; 250 lg/h plus additional boluses of 250 lg before starting the infusion and every 6 hours throughout the infusion period) and a continuous intravenous infusion of proton pump inhibitor (PPI) omeprazole 80 mg/10 hours after an initial bolus of 80 mg. After diagnostic endoscopy, SMT infusion was maintained for 5 days in patients with AVB and PPI infusion was maintained for 72 hours in those with PUB followed by oral administration. All patients were also treated with antibiotic prophylaxis with oral norfloxacin (400 mg twice-daily) or intravenous ceftriaxone (1 g/d), which were maintained for 5 days.
Emergency gastroscopy was performed within the first 6 hours of admission under conscious sedation with propofol. When endoscopy disclosed bleeding esophageal varices, band ligation was performed during the same procedure with a multiband ligating device. Each varix was ligated at least once, and up to 14 bands were placed. Ligation was started in the gastroesophageal junction or at the site of bleeding when it was identified, with subsequent ligatures applied proximally within the distal esophagus. When endoscopy disclosed a peptic ulcer with active arterial bleeding (Forrest Ia-Ib), a nonbleeding visible vessel (Forrest IIa), or an adherent clot (Forrest IIb), patients underwent endoscopic therapy with adrenaline injection plus multipolar electrocoagulation or clips or a second sclerosant injection (ethanolamine or polidocanol).
All patients included in the study were admitted to a gastrointestinal bleeding unit for close monitoring. Hemoglobin concentration was measured every 8-12 hours during the first 2 days and every day thereafter. Hemoglobin was also determined when further bleeding was suspected. Transfusion of units of packed red cells was administered to maintain hemoglobin levels at approximately 8 g/dL. Hepatic imaging studies (mainly ultrasonography) and, in some patients, hemodynamic studies to assess the hepatic venous pressure gradient (HVPG) were performed during the first 5 days.
In patients with AVB, once SMT infusion was completed, those surviving were treated with b-blockers 6 isosorbide mononitrate plus elective endoscopic ligation for the prevention of variceal rebleeding. Sessions of endoscopic variceal ligation were conducted every 3-4 weeks until variceal eradication.
In patients with PUB, once PPI infusion was completed, a single daily dose of oral PPI was administered during a variable time period according to the underlying ulcer etiology. In all cases, PPI therapy was maintained at least 4 weeks for a duodenal ulcer and 8 weeks for a gastric ulcer. Helicobacter pylori infection, when documented, was treated with first-line antibiotic therapy (based on PPI plus clarithromycin and amoxicillin or metronidazole) during 10 days. In these patients, PPI therapy could be discontinued once H. pylori eradication was documented. In patients with acetylsalicylic acid/ nonsteroidal anti-inflammatory drugs (ASA/NSAIDs)-related ulcers who required long-term therapy with these drugs, maintenance therapy with PPI was associated during such treatment. In patients with idiopathic ulcers, not related to H. pylori or NSAID/ASA, maintenance PPI therapy was prescribed indefinitely. In patients with AVB, therapy with PPI was maintained until the elective endoscopic ligation program was completed. In patients with gastric ulcers, ulcer biopsy was performed at admission to rule out malignancy. A repeated followup endoscopy at 8 weeks was scheduled only in these patients. Those with an unhealed ulcer at follow-up examination underwent repeated biopsy.
All the patients included were followed up to day 45 after inclusion in the study.
OUTCOME MEASURES AND DEFINITIONS
The primary outcome measure was death from any cause within the first 45 days after admission. Secondary outcomes included the rate of further bleeding within the first 5 days, use of rescue therapies to control further bleeding, rebleeding from 5 to 45 days, and 1-year survival. Bleeding-related events were defined according to consensuated guidelines. (18) (19) (20) (21) Further bleeding included failure to control bleeding and/or early rebleeding and was defined as hematemesis or fresh melena, associated with hemodynamic instability (systolic blood pressure <100 mm Hg and/or pulse rate >100 bpm) and/or hemoglobin drop 2 g/dL within a 6-hour period. Control of acute bleeding was defined when criteria for further bleeding did not occur within the first 24 hours of hospital admission. Early rebleeding was defined when these criteria occurred between 24 hours after admission and within the first 5 days. Further bleeding was considered therapeutic failure and was treated with repeated endoscopic therapy or emergency surgery in the case of PUB, whereas TIPS was considered in the case of further AVB. AVB was defined by emergency endoscopy according to Baveno IV-V criteria. PUB was defined according to international consensus when endoscopy disclosed an ulcer with active arterial bleeding, a nonbleeding visible vessel, or an adherent clot. Active bleeding was defined as a continuous flow of blood pumping or oozing from the ulcer floor. Nonbleeding visible vessel was defined as a protuberant mound on the ulcer base. When endoscopy disclosed both clean varices and a peptic ulcer with a clean base, the ulcer was considered to be the source of bleeding. This was decided considering that peptic ulcer is an acute lesion (that may evolve to healing or complication) whereas varices have a chronic course. Furthermore, according to current guidelines, when no bleeding stigmata is observed, AVB can only be diagnosed in the absence of any other potential source of bleeding. (18, 19) Complications were defined as any untoward event requiring active therapy or prolonged hospitalization. Complications were considered severe if the health or safety of the patient was endangered (i.e., pneumonia, sepsis, bacterial peritonitis, or bleeding from esophageal ulcers). Symptoms that did not merit investigation or treatment were not considered complications.
STATISTICAL ANALYSIS
Categorical variables were compared using Fisher's exact test. Continuous variables, reported as mean 6 SD, were compared using the Student t test, and the Wilcoxon rank-sum test was used for skewed or ordinal data. Actuarial probabilities were calculated using the Kaplan-Meier method, and event rates of endpoints were compared with the use of the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated with the Cox proportional-hazard model. The Cox regression model was also used to compare the two groups (AVB and PUB) with respect to primary and secondary endpoints adjusting for baseline risk factors. Data were censored at the time of the endpoint, last visit, or end of follow-up, whichever occurred earliest. Candidate prognostic variables for each outcome of interest included those already known as predictive from previous studies. The relationship between the cause of bleeding and baseline variables (plus development of further bleeding), with respect to the risk of the outcome, was analyzed including factors significantly associated with the outcome in the univariate analysis (with P values <0.05). To reduce the risk of overfitting the prognostic models, it was stated that the ratio of candidate prognostic variables to the number of observed events should be 1:10 or less in each final model. Colinearity was assessed with the tolerance value and the variance inflation factor.
Step-wise regression analyses were performed with the backward procedure. The Cox model was also used to investigate the consistency of the effect of the cause of bleeding (AVB or PUB) on the primary outcome, by testing for two-way interactions between the cause of bleeding and each baseline factor associated with death on univariate analysis. All P values were twotailed, and values 0.05 were considered to indicate statistical significance. Calculations were performed using the SPSS 19.0 statistical package (SPSS, Chicago, IL).
Results
During the study period, a total of 926 consecutive patients with cirrhosis and UGIB who fulfilled the inclusion and exclusion criteria were screened at the five participating centers and 136 of them were excluded, mainly because of bleeding from different sources than peptic ulcer or esophageal varices (Supporting Appendix). Finally, 790 were selected for inclusion in the study, 646 of them bleeding from esophageal varices and 144 bleeding from a peptic ulcer. The characteristics of patients in both groups at the time of inclusion are summarized in Table 1 . Patients with PUB were older than those with AVB, had greater rates of NSAID use and anticoagulant use, a higher Charlson index, and morefrequent gastric varices. Patients with AVB had morefrequent previous bleeding episodes, a greater use of bblockers, and higher rates of shock and ascites at admission than those with PUB. Time from start of symptoms to hospital admission was shorter in patients with AVB than in those with PUB. There was a trend toward higher rates of alcoholic etiology of cirrhosis among those with PUB. Liver function, assessed by Child-Pugh score and by Model for End-Stage Liver Disease (MELD) score, was similar in both groups. Other baseline characteristics were also similar between groups (Table 1 ). In the subgroup of patients who had portal pressure measurements, the HVPG was higher in those with AVB than in those with PUB (Table 1) and was 10 mm Hg in all cases except in 2 patients (7%) with PUB. Endoscopic therapy was given more frequently to patients with AVB than to those with PUB: 572 (88%) versus 88 (61%; P < 0.001). Endoscopic therapy was not performed in 74 patients (12%) with AVB because of a decision of the attending physician. *Plus-minus values are means 6 SD. † Hypovolemic shock was defined as systolic blood pressure <100 mm Hg and heart rate >100 bpm. ‡ Portal pressure was measured by the HVPG, the difference between the wedged and free hepatic venous pressure. Measurements were performed within the first 5 days in a subgroup of 274 patients admitted to one of the participating hospitals, 248 with variceal bleeding and 26 with PUB. § Measurements were performed in a subgroup of 274 patients admitted to one of the participating hospitals, 248 with variceal bleeding and 26 with PUB. ¶ In patients of the AVB group, a white nipple was observed in 150 cases (23%) and an adherent clot was observed in 65 cases (10%). In patients of the PUB group, a visible vessel was observed in 44 cases (30%) and an adherent clot was observed in 9 cases (6%). k ACLF 5 presence of acute on chronic liver failure at admission, defined according to CLIF criteria. # Bacterial infections diagnosed at admission or during the first 7 days. Abbreviation: INR, international normalized ratio.
FIG. 1.
Overall survival according to the cause of bleeding. (A) shows the Kaplan-Meier estimates of 6-week survival in both groups. The inset figure shows the same data on an enlarged y axis. The probability was similar in both groups (P 5 0.48 by the log-rank test). (B) shows hazard ratios with the 95% CI for death according to prespecified subgroups.
Cirrhosis had not been diagnosed before hemorrhage in 115 patients (18%) with AVB and in 36 (26%) with PUB (P 5 0.04). Among patients with cirrhosis already known at admission, 491 (92%) of those with AVB versus 39 (36%) of those with PUB had large varices at emergency endoscopy (P < 0.001) and, respectively, 168 (32%) versus 25 (23%) patients had previous variceal bleeding (P 5 0.08) and 223 (42%) versus 35 (32%) patients (P 5 0.07) were on treatment with b-blockers. Up to 34% of PUB patients had no esophageal varices.
In 112 patients, both esophageal varices and peptic ulcer were identified at endoscopy. Among them, 70 patients had ulcers with bleeding stigmata defining PUB (33 had active bleeding, 31 a nonbleeding visible vessel, and 6 had an adherent clot) and 17 fulfilled diagnostic criteria of AVB (11 had active variceal bleeding and 6 had a white nipple on a varix). In 25 patients, both a peptic ulcer and varices coexisted without bleeding stigmata in either of the two lesions and bleeding was attributed to PUB.
Among patients with PUB, ulcer was related with NSAID or with ASA in 51 patients (35%) and was related with H. pylori infection in 42 (29%; 15 of them also had NSAID/ASA use) and was idiopathic in the remaining 66 patients (46%). Ulcer location was duodenal in 79 patients (55%), gastric in 62 (43%), and stomal in 3 (2%). In patients with PUB, endoscopic therapy was performed in 88 patients: 41 with active bleeding (Forrest Ia-Ib); 37 with a nonbleeding visible vessel (Forrest IIa); and in 10 with an adherent clot (Forrest IIb). No malignancy was observed in the biopsies performed at the index endoscopy or during follow-up.
MORTALITY
Risk of mortality at 6 weeks was similar in the group of patients with AVB and in the group of patients with PUB ( Fig. 1; Table 2 ): death occurred in 122 patients (19%) with AVB and in 24 (17%) with PUB (odds ratio [OR] 5 0.85; 95% CI 5 0.55-1.33; P 5 0.48). A similar risk of death between patients with AVB and those with PUB was consistently observed across different subgroups according to liver dysfunction, etiology of cirrhosis, and in-hospital bleeding (Table 2) .
This risk of mortality was still similar in the two groups of patients after adjustment for baseline risk factors for death (OR 5 0.96; 95% CI 5 0.76-2.01). Different parameters, among which there was not the cause of bleeding, were related to the risk of death (Table 3) . Variables with an independent capacity to predict death at admission were: Child-Pugh score, MELD score, acute kidney injury (AKI), acute on chronic liver failure (ACLF), presence of shock, inhospital bleeding, Rockall score, the presence of bacterial infection, and development of further bleeding (Table 3) . No two-way interactions between the cause of bleeding (AVB or PUB) and each one of the other variables were detected (Supporting Appendix). Parameters with a potential influence on death, such as liver dysfunction, the presence of bacterial infection at admission, the presence of AKI, ACLF, multiorgan failure, or the presence of further bleeding had a similar distribution among patients who died in the two groups (Table 4) . Only 3 patients (2%) with PUB versus 22 (3%) with AVB died with uncontrolled bleeding 
FIG. 2. Therapeutic failure according to the cause of bleeding. (A) shows the
Kaplan-Meier estimates of remaining without 5 days failure to control bleeding in both groups. The probability was significantly higher in patients with ulcer bleeding than in those with variceal bleeding (P 5 0.01 by log-rank test). (B) shows the Kaplan-Meier estimates of remaining without rebleeding at 6 weeks in both groups. The probability was significantly higher in patients with ulcer bleeding than in those with variceal bleeding (P < 0.001 by log-rank test).
(P 5 0.39), whereas the majority of patients in each group died from liver failure or because of other organ failure with the bleeding episode under control (Table  5) . Half of the patients who died in each group had ACLF at admission, and, among them, 5 of those with PUB (21%) and 33 of those with AVB (27%) had ACLF grade 2 or 3 according to Chronic Liver Failure criteria (P 5 0.53). Among the patients who died in each group without ACLF at admission, 5 with PUB (42%) versus 25 (40%) with AVB developed renal dysfunction before death (P 5 1.0), respectively, and 8 (67%) versus 36 (58%) had comorbidities (P 5 0.17) with a Charlson index 8 in 6 (50%) versus 29 (47%) patients (P 5 1.0). In 25 patients both a peptic ulcer and varices coexisted without bleeding stigmata in either of the two lesions. When these patients were excluded and only those with a confirmed source of bleeding were included in the analysis (i.e., those with a single lesion or those who despite having both lesions had bleeding stigmata in 1 of them), mortality at 6 weeks was also similar in both groups of patients. In this subgroup, death occurred in 122 patients (19%) with variceal bleeding and in 21 (18%) with ulcer bleeding (OR 5 0.92; 95% CI 5 0.55-1.53; P 5 0.75).
When follow-up was extended to 1 year, risk of mortality was also similar in patients with PUB and in those with AVB (Supporting Appendix): At 1 year, death occurred in 175 patients (27%) with AVB and in 34 (24%) with PUB (HR 5 0.87; 95% CI 5 0.60-1.26; P 5 0.47).
FURTHER BLEEDING
Rate of further bleeding was significantly lower in patients with PUB than in those with AVB (Fig. 2) , occurring in 14 (10%) versus 119 (18%) patients, respectively (OR 5 0.50; 95% CI 5 0.29-0.88). The risk of further bleeding was also lower in patients with PUB after adjustment for baseline risk factors for further bleeding (OR 5 0.48; 95% CI 5 0.25-0.96). In addition to the source of bleeding, the Child-Pugh score, presence of shock, bacterial infection, Rockall score, and hemoglobin at admission also had an independent capacity to predict further bleeding (Supporting Appendix). The lower risk of further bleeding in patients with PUB than in those with AVB was consistent across subgroups and appeared to be particularly pronounced in patients with less-advanced liver dysfunction (Child-Pugh class A/B), in those with nonalcoholic cirrhosis, and in those admitted because of bleeding ( Table 2) .
The overall risk of rebleeding at 45 days was significantly higher in patients with AVB than in those with PUB, occurring in 167 (26%) versus 15 (10%) patients, respectively (HR 5 2.63; 95% CI 5 1.55-4.47; P 5 0.01; Fig. 2 ). In patients with AVB, all the rebleeding episodes were attributed to varices, except in 9 patients who had rebleeding from endoscopic variceal ligationrelated esophageal ulcers. In patients with PUB, all the rebleeding episodes were from peptic ulcer, except in 2 patients who had late rebleeding (after 10 days) from esophageal varices.
Among patients with AVB, rescue therapy with balloon tamponade and/or with TIPS was frequently required (Table 2 ). Among patients with PUB who had further bleeding, a second endoscopic treatment was carried out in up to 79% of cases, whereas salvage surgery was performed in 2 patients (14%) and arterial embolization in another 3 (21%). Among patients with further bleeding, a new rebleeding episode occurred in 6 patients (43%) with PUB and in 35 (29%) with AVB (P 5 0.56). Among patients with further bleeding, death occurred in 10 patients (71%) with PUB and in 58 (49%) with AVB (P 5 0.15).
Overall transfusion requirements were similar in both groups of patients, although there was a trend toward higher transfusion requirement in patients with PUB than in those with AVB in the subgroup of patients with further bleeding (Table 2 ). Length of hospital stay was shorter in patients with PUB than in those with AVB.
ADVERSE EVENTS
Overall incidence of complications was similar in patients with PUB and in those with AVB, as was the incidence of serious adverse events (Table 6 ). Bacterial infections and acute kidney failure were the more frequent complications and had a similar incidence in both groups. Other adverse events were also similar between groups.
Discussion
The present study shows that, using current firstline therapy, the survival of patients with cirrhosis and PUB is similar to that of those with AVB. The risk of further bleeding is significantly higher in patients with AVB than in those with PUB. However, only a small proportion of patients died from uncontrolled hemorrhage, including those with variceal or ulcer bleeding, whereas the majority died from comorbidities, from complications related to bleeding or because of liver failure.
A decrease in overall mortality rates from UGIB has been documented in recent years, both in patients with PUB and in those with AVB. (5) (6) (7) This can be related to improvements in the general therapeutic management of critically ill patients, as well as to improvements in specific hemostatic therapies. (8, 16, 17) However, current mortality rates are still non-negligible and are frequently related to comorbidities rather than to uncontrolled bleeding. (9) (10) (11) (12) (13) This has been shown in patients with PUB and in those with AVB. (11) (12) (13) In patients with PUB, concurrent comorbidity is currently a major contributor to mortality, and, among such comorbidities, chronic liver disease has a relevant role. (9, 11) Mortality rates of up to 15%-20% have been reported in patients with liver cirrhosis bleeding from peptic ulcers. (2, 3, 15) Such mortality rates are much higher than those observed in patients with PUB who have no comorbidities. (8, 9) On the other hand, these mortality rates are comparable to those observed in patients with cirrhosis with AVB using the currently recommended first-line therapy with a combination of vasoactive drugs, endoscopic ligation, and antibiotic prophylaxis. (13, 14) In concordance with this, the present study clearly suggests that, among patients with cirrhosis and UGIB, the risk of death is similar whether the source of hemorrhage is a peptic ulcer or whether it is variceal. Previous studies, using the currently consensuated recommendations for treating AVB, have observed that death is attributed to uncontrolled bleeding in only a small proportion of cases, which is probably related to the high hemostatic efficacy of available therapies with which further bleeding only occurs in around 15% of cases. (13, 14, 22) In the majority of cases, mortality is related to complications derived from bleeding or to comorbidities. (13, 22) Accordingly, in the present study, we also observed that death was attributed to uncontrolled bleeding in only a small proportion of patients, both in those with AVB and in those with PUB. In more than 80% of cases, death was related to liver failure or to complications derived from hemorrhage, with bleeding under control. This suggests that in patients with cirrhosis and UGIB, whatever the cause of bleeding, mortality is mainly attributed to the detrimental impact of acute bleeding on liver function, or to the development of complications such as bacterial infections, kidney injury, or other organ failures associated with decompensated cirrhosis, or is attributed to comorbidities worsened as a result of these complications. Accordingly, in the present study, we observed a similar hepatic dysfunction and a similar incidence of bacterial infections, organ failures, and ACLF in patients with PUB and in those with AVB. Furthermore, among patients who died, the incidence of these parameters potentially related to death was also similar in both groups of patients, as well as the cause to which death was finally attributed. All these factors may help to explain why, as suggested by our results, the risk of mortality in patients with cirrhosis and UGIB is similar whatever the source of bleeding, whether from esophageal varices or a peptic ulcer. This reinforces the assertion that the level of care and general management of patients with cirrhosis with UGIB should be the same in those with PUB as in those with AVB, requiring close monitoring and measures to prevent or treat complications, which may influence the final outcome. (16, 17) The rates of further bleeding observed In both groups were similar to those previously reported for each of these hemorrhagic sources. (8, 16, 17) Such a further bleeding rate was significantly higher in patients with AVB than in those with PUB. However, the lower rate of failure observed in patients with PUB did not translate into better survival. This may be related to the fact that, among patients who had further bleeding, there was a trend toward a greater mortality in those with PUB than in those with AVB, which may be attributed to the availability of effective rescue therapies, such as TIPS, when variceal rebleeding occurs. On the other hand, further bleeding was clearly associated with death in both groups of patients and occurred in between 40% and 50% of those who died. This suggest that, even though bleeding is finally controlled in the majority of cases, further bleeding may have detrimental effects on liver function and may also induce other organ failure, particularly when the definitive control of bleeding is difficult such as in patients with recurrent PUB. In 2010 a randomized, controlled trial (RCT) shown that, in selected high-risk patients with AVB, early preventive TIPS may avoid further bleeding and improve survival. (23) In keeping with this, recent guidelines recommend to consider early TIPS in patients with AVB at high risk of failure. (24) However, the present study was performed before implementation of early TIPS, with the RCT suggesting efficacy appearing in the very last period of the study. On the other hand, observational studies also suggest that, in selected high-risk patients with PUB, a second preventive endoscopic therapy or angiographic therapy could be valuable. (8) Future studies should be performed to investigate how these promising therapies may impact prognosis in patients with cirrhosis with both AVB or PUB.
Recent studies suggest that advanced cirrhosis, among other comorbidities, may increase the risk of nonvariceal bleeding attributed to peptic ulcer and nonulcer lesions. (1, 25) Several factors may predispose patients with cirrhosis to bleed from nonvariceal sources, such as an impaired mucosal defence, thrombocytopenia, vascular dysfunction, associated bacterial infections, or renal impairment. (26) (27) (28) (29) (30) Furthermore, several studies have also observed that a large proportion of peptic ulcers in cirrhosis are idiopathic and not related to H. pylori infection or to the use of NSAIDs. (1, 31) It has been suggested that the physiopathology of peptic ulcer in cirrhosis may involve, at least in part, a relationship with PHT, which may favor the impairment of gastric mucosal defences. (26, 30, 31) In concordance with this, in the present study, we found clinically significant PHT in the majority of patients with PUB. In the subgroup of patients who had measurements of HVPG, portal pressure was lower in those with PUB than in those with AVB. However, in the majority of patients with PUB (93% of cases), the HVPG was greater than 10 mm Hg (which is the level defining clinically significant PHT) and was even 12 mm Hg (the level related with risk of bleeding from portal hypertensive lesions, such as esophageal varices). Studies in experimental models also suggest that PHT may induce gastric mucosal ulceration and hemorrhage. (32) (33) (34) This is a relevant issue that should be clarified in future studies, which should elucidate the relationship of PHT and PUB in cirrhosis, as well as its derived therapeutic implications. In this regard, a recent cohort study has demonstrated that liver cirrhosis is associated with an increased long-term risk of recurrent PUB, which may be related to PHT.
(1) This study has also suggested that the concomitant use of bblockers may be linked with a reduction in the longterm risk of recurrent PUB in cirrhosis, which has not been observed with H. pylori eradication or with the maintenance of antisecretory therapy. (1, 35, 36) The present study has several potential limitations. It is a retrospective, multicenter cohort study using a prospective register of data, which have several limitations intrinsic to this type of analysis. The variable quality of data may impose difficulties in interpretation. However, the prospective register of patients through well-organized entry registries and following a clear protocol guarantees the quality of the information for analysis, as well as the objectivity of the primary outcome. Another potential limitation, considering the observational design of this study, can be the risk of selection bias. However, the participating hospitals consecutively considered all patients with cirrhosis with confirmed UGIB using few exclusion criteria to adapt the study to the real-world setting. Only 15% of eligible patients were excluded, mainly because of bleeding from sources other than peptic ulcers or esophageal varices. This was done to avoid heterogeneity of the patient population, given that different prognostic implications can exist in such cases. Another potential limitation is that the results cannot be generalized to all patients with PHT, given that patients with noncirrhotic PHT were not included. The prognosis of AVB is better in such patients than in those with cirrhosis, and this may also be the case in patients with ulcer bleeding. The limited diagnostic accuracy when both lesions (esophageal varices and peptic ulcer) coexist without any bleeding stigmata also may have introduced bias into the study. This occurred in 25 patients (3% of the included). In these patients, the hemorrhage was attributed to peptic ulcer because this is a lesion with a relatively acute course leading to healing or to a complication, whereas varices follow a chronic course. Furthermore, attending to current guidelines, when no bleeding stigmata is observed variceal hemorrhage can only be diagnosed in the absence of any other potential source of bleeding. Nevertheless, in patients in whom both lesions coexist without any bleeding stigmata, the diagnosis of the source of bleeding cannot be certain and this may have led to a bias. However, when the analysis was restricted only to patients with bleeding stigmata and thus with a certain diagnosis, similar results were observed.
In conclusion, the present study shows that the survival of patients with cirrhosis and PUB is similar to that of those with AVB. Although the risk of further bleeding was significantly higher in patients with AVB, only a small proportion of patients died from an uncontrolled hemorrhage, either among those with variceal or ulcer bleeding, whereas the majority died from comorbidities, complications related to bleeding, or because of liver failure. This suggests that, in order to improve the survival of patients with acute UGIB, whether PUB or AVB, future efforts should focus on measures to limit the impact of bleeding on liver dysfunction, on complications related to bleeding, and on comorbidities.
